503A vs 503B Compounding Pharmacies: What It Means for Your Peptide or GLP-1 Prescription

Key takeaways

• 503A and 503B are two sections of federal drug law that let compounded drugs skip FDA approval. A 503A pharmacy is licensed by a state and compounds for an identified patient on a prescription; a 503B outsourcing facility registers with FDA, must follow manufacturing-grade quality rules (cGMP) and may ship batches to clinics as office stock.
• Oversight differs: state boards of pharmacy have primary responsibility for 503A pharmacies, which are exempt from cGMP; FDA inspects 503B facilities on a risk-based schedule and requires adverse-event and product reports. Neither lane makes a compounded drug FDA-approved.
• Ingredient rules differ: a 503A pharmacy may use a substance with a USP monograph, a component of an approved drug or one on FDA's 503A list; a 503B facility only one on FDA's 503B list (five substances, none a peptide) or a drug in shortage. Biological products, including tesamorelin and hCG, are eligible for neither.
• For GLP-1s in 2026 the difference is decisive: with the shortages over, 503B facilities have no basis to make tirzepatide or semaglutide from bulk, FDA proposed on May 1, 2026 to keep it that way, and 503A pharmacies may compound them only for a documented patient-specific need.
• For most legitimate peptide prescriptions (sermorelin, PT-141, glutathione) the lane is 503A. 'Which is better' matters less than whether the substance may be compounded at all and whether the specific pharmacy is licensed and clean.

If a compounding pharmacy fills your prescription, it works in one of two lanes federal law created: section 503A, for state-licensed pharmacies compounding for individual patients, or section 503B, for FDA-registered outsourcing facilities that make batches under manufacturing rules. The lanes differ in who inspects them, which quality standard applies, which ingredients they may use and whether they need your name on a prescription. This guide explains each from the statute and FDA's own pages, read on October 10, 2026. To check a specific pharmacy, use our guide to verifying a compounding pharmacy's license and testing; for tirzepatide, read how to check a tirzepatide compounding pharmacy. Which substances may be compounded at all is in our legal tracker.

503A vs 503B at a glance

Sources: (21 U.S.C. 353a) (21 U.S.C. 353b) (FDA compounding Q&A) (FDA outsourcing facilities) (FDA prescription guidance).

Why there are two lanes

Section 503A is the older rule. It describes traditional pharmacy compounding: a pharmacist preparing a drug for one patient because the approved product does not suit that person. Compounded drugs that meet its conditions are exempt from three requirements that bind drug manufacturers: FDA approval before marketing, labeling with adequate directions for use, and current good manufacturing practice (21 U.S.C. 353a).

Some compounders had grown far beyond that model. In 2012, preservative-free methylprednisolone injections made by a single compounding pharmacy caused a multistate outbreak of fungal infections: as of July 1, 2013, 749 cases in 20 states and 61 deaths had been reported, among 13,534 people potentially exposed (Smith 2013). The Drug Quality and Security Act, signed on November 27, 2013, created section 503B and the category of outsourcing facility (FDA outsourcing facilities): compounders that may make sterile drugs in volume, without patient-specific prescriptions, if they accept FDA registration, inspection and manufacturing-grade quality rules. Outsourcing facilities are exempt from the approval and labeling requirements and from the drug supply-chain tracing rules, but not from cGMP (21 U.S.C. 353b).

The 503A lane: one patient, one prescription

A 503A drug is compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, on a valid prescription for an identified individual patient. The pharmacy may compound limited quantities before a prescription arrives, but only based on a history of receiving prescriptions for that drug within an established relationship with the patient or prescriber (21 U.S.C. 353a).

That requirement is why a 503A pharmacy cannot supply office stock: FDA's guidance says prescriptions without patient names do not qualify, and that clinics needing compounded drugs on hand should get them from outsourcing facilities (FDA prescription guidance).

The ingredient rules are the three tests that decide most peptide questions. A bulk substance must comply with a USP or National Formulary monograph if one exists; otherwise it must be a component of an FDA-approved drug or appear on FDA's 503A bulks list. It must also come from an FDA-registered manufacturer with a valid certificate of analysis (21 U.S.C. 353a). The 503A list holds six substances, none a peptide, and FDA tolerates some nominated substances (its Category 1) while it evaluates them; our Category 2 explainer covers those lists.

Oversight is mainly local. State boards of pharmacy have primary responsibility for pharmacies that are not outsourcing facilities, and FDA runs surveillance and for-cause inspections (FDA compounding Q&A). Federal law does not require these pharmacies to report adverse events to FDA, one reason FDA considers adverse events from compounded GLP-1s underreported (FDA GLP-1 page).

The 503B lane: batches under FDA oversight

An outsourcing facility is a facility at one address that compounds sterile drugs, has elected to register with FDA and complies with all of section 503B. It need not be a licensed pharmacy, and it may or may not obtain prescriptions for identified patients (21 U.S.C. 353b). In exchange, the law adds obligations a pharmacy does not have:

• Registration every year, between October 1 and December 31, with a fee; a facility that does not re-register drops off FDA's list on January 1 (FDA registered facilities).
• cGMP and FDA inspection on a risk-based schedule that weighs compliance history, recalls and the inherent risk of the drugs made (21 U.S.C. 353b).
• Reporting: adverse events, and every June and December a list of the drugs compounded in the previous six months (FDA outsourcing facilities).
• Labels that say 'This is a compounded drug', with the facility's name, address and phone number, lot number, expiration date and storage instructions, plus 'Office Use Only' when the drug is not dispensed on a patient prescription. No one else may resell the facility's drugs, though a clinic may administer them (21 U.S.C. 353b).

The ingredient rule is narrower than in 503A. A 503B facility may compound from a bulk substance only if it is on FDA's 503B bulks list of substances with a demonstrated clinical need, or if the drug is on FDA's shortage list when it is compounded, distributed and dispensed (FDA 503B bulks). The list has five entries, all topical except oral quinacrine; none is a peptide. FDA also tolerates some nominated substances while it evaluates them, and keeps a 503B Category 2 of safety concerns that includes ipamorelin, GHRP-2 and GHRP-6 (Category 2 explainer).

Registration is not inspection. On FDA's list updated September 30, 2026, we counted roughly 100 registered facilities, 42 of them marked 'not yet inspected', and many of the inspected ones had received a Form 483, the list of objectionable conditions investigators hand over at the end of an inspection, which FDA notes is not a final agency determination (FDA registered facilities).

cGMP versus USP standards: what the quality gap means

The federal cGMP regulations (21 CFR parts 210 and 211) are the rules drug manufacturers follow. FDA's 2026 warning letters show what they demand: a quality control unit responsible for identity, strength, quality and purity, validated aseptic processes, environmental monitoring and written production controls (Empower letter). FDA's guidance on applying cGMP to outsourcing facilities is still a revised draft (ProRx letter).

A 503A pharmacy is exempt. Its federal floor is ingredients that meet USP or National Formulary standards and the USP chapter on pharmacy compounding (21 U.S.C. 353a); in practice, USP chapter 795 for nonsterile and chapter 797 for sterile preparations such as injectables, enforced by state boards. FDA's summary is that outsourcing facilities face increased quality standards, and that the ban on preparing drugs under insanitary conditions applies to every compounder (FDA compounding Q&A).

Two cautions. Stricter on paper is not clean in practice: in April 2026 FDA described a registered outsourcing facility that had recalled tirzepatide and semaglutide lots in October 2025 for lack of sterility assurance (ProRx letter). And a 503A pharmacy that compounds outside the section loses its exemption: in September 2026 FDA told a large 503A pharmacy that its high-volume GLP-1 products were subject to cGMP because they did not qualify (Empower letter).

What each lane may make: peptides and GLP-1s

Sources: (FDA GLP-1 page) (FDA 503B bulks) (Federal Register, May 2026); peptide statuses follow the legal tracker.

The biological products row deserves its own sentence. Biological products are not eligible for the exemptions in either section, and since March 23, 2020 that includes protein drugs whose old approvals were deemed biologics licenses (FDA notice, 2020). FDA answers the question 'can biologics be compounded?' with one word, no (FDA compounding Q&A). That is why tesamorelin, a 44-amino-acid protein, is lawful only as brand Egrifta, as our tesamorelin profile explains.

The 'essentially a copy' limits

Both sections stop compounders from replacing approved drugs, but they draw the line differently.

503A. A pharmacy may not compound 'regularly or in inordinate amounts' drugs that are essentially copies of a commercially available product, and a product is not a copy if the prescriber determines that a change made for an identified patient produces a significant difference for that patient (21 U.S.C. 353a). FDA treats a compounded drug as a copy when it has the same active ingredient, the same route and a strength within 10 percent or easily substitutable. It expects the prescriber's reason on the prescription ('No Dye X, patient allergy' is its example), says a lower price is not enough, and does not count four or fewer prescriptions of a copy in a calendar month as compounding regularly (FDA 503A copies guidance).

503B. A drug identical or nearly identical to an approved drug (same active ingredient, route, dosage form, strength and excipients) is a copy unless the approved drug is in shortage, and no prescriber statement changes that. A drug that merely shares the bulk ingredient is a copy unless a prescriber determines a clinical difference for an individual patient (21 U.S.C. 353b) (FDA 503B copies guidance).

FDA's September 2026 letter shows how it reads these words: significant-difference statements repeated verbatim across many prescriptions, or picked from a telehealth platform's menu, call the individual judgment into question, and high volume suggests the differences are pretextual (Empower letter).

What it means for a GLP-1 prescription in 2026

While tirzepatide and semaglutide were on FDA's shortage list, both lanes could compound copies. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025; the grace periods for outsourcing facilities ended on March 19 and May 22, 2025 (legal tracker).

• 503B is closed for bulk GLP-1s. Neither drug is in shortage or on the 503B list. In April 2026 FDA warned a registered outsourcing facility that tirzepatide it had compounded from bulk was ineligible for the 503B exemptions for exactly that reason (ProRx letter). On May 1, 2026 FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B list, saying it does not consider cost or convenience when judging clinical need (Federal Register, May 2026). Comments closed July 30, 2026; no final decision had appeared by October 9.
• 503A is open only narrowly. A pharmacy may compound tirzepatide for an identified patient whose prescriber documents a significant difference from Zepbound or Mounjaro, such as an allergy to an inactive ingredient. Routine copies with a vitamin added are what the September 2026 letter targeted. Our compounded tirzepatide legal explainer walks through what qualifies.
• The safety record is incomplete. As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, numbers it expects are low because 503A pharmacies are not required to report (FDA GLP-1 page).

A tirzepatide product described as coming from a 503B facility in 2026 is therefore a reason to ask more questions, not fewer. The tirzepatide pharmacy guide lists the red flags.

What it means for a peptide prescription

For the peptides a pharmacy may legally make, the usual route is 503A: a clinician licensed in your state writes a prescription, and a 503A pharmacy compounds a vial with your name on the label. That is how sermorelin is prescribed. A peptide that fails the 503A tests, such as BPC-157, does not become legal at an outsourcing facility, whose list is even shorter. A vial sold as 'research use only' is in neither lane. The end-to-end process is in our complete guide to peptide therapy.

Is 503A or 503B better?

It depends on what you need. For your own prescription, 503A is the lane the law designed; a 503B facility can fill patient prescriptions too, but for most peptides it has no listed bulk ingredient to start from. For a clinic's office stock, 503B is the only lawful source. For quality assurance, 503B adds cGMP, FDA inspection and mandatory adverse event reporting, real advantages that make outsourcing-facility product cost more (peptide therapy cost guide). For GLP-1s in 2026 the comparison does not arise: only a documented 503A prescription is lawful. The questions that matter more are whether the substance may be compounded at all and whether the specific pharmacy is licensed, inspected and honest about what it is.

How to tell which lane filled your prescription

1. Read the label. A 503B label must say 'This is a compounded drug' and name the facility; 'Office Use Only' means it was not dispensed for you (21 U.S.C. 353b). A 503A vial carries your name and a prescription number.
2. Ask the prescriber which pharmacy compounds the drug, in which state, and whether it is 503A or 503B.
3. Look it up on FDA's registered list or your state board's license search; the verification guide has the links.
4. Dose from the label concentration, using our peptide calculator.

Bottom line

503A and 503B are not quality grades; they are two legal lanes. A 503A pharmacy compounds for you, on your prescription, under its state board and USP standards. A 503B outsourcing facility makes batches under FDA registration, cGMP and inspection, and may supply clinics. Neither product is FDA-approved, neither lane may compound a biological product, and in 2026 neither may make routine copies of tirzepatide or semaglutide. Ask which lane your prescription uses, then check the pharmacy itself: the better one is the one allowed to make your drug that does it cleanly.

Frequently asked questions

+−What is the difference between 503A and 503B?

A 503A pharmacy is licensed by a state and compounds for an identified patient on a prescription; it is exempt from federal manufacturing rules (cGMP) and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility registers with FDA every year, must follow cGMP, is inspected by FDA on a risk-based schedule, reports adverse events and product lists to FDA, and may make batches without patient prescriptions for clinics to keep as office stock. Neither kind of product is FDA-approved.

+−Is 503A or 503B better?

Neither is better in general. 503B facilities are held to stricter, manufacturing-grade quality rules and FDA inspection, and they are the only lawful source of compounded office stock for clinics. A 503A pharmacy is the lane designed for an individual prescription, and in 2026 it is the only lane in which compounded tirzepatide or semaglutide can still be made, and only for a documented patient-specific need. What matters more is whether the substance may be compounded at all and whether the specific pharmacy is licensed and has a clean inspection record.

+−Can a 503B outsourcing facility compound tirzepatide or semaglutide?

Not from bulk drug substance in 2026. A 503B facility may compound from a bulk ingredient only if it is on FDA's 503B bulks list or the drug is on FDA's shortage list. The tirzepatide and semaglutide shortages ended in December 2024 and February 2025, neither drug is on the list, and on May 1, 2026 FDA proposed not to add them. In April 2026 FDA warned a registered outsourcing facility for compounding tirzepatide from bulk.

+−Can 503A compounding pharmacies make peptides?

Yes, if the peptide passes one of the three tests in section 503A: it has a USP monograph, it is a component of an FDA-approved drug, or it appears on FDA's 503A bulks list. Sermorelin and bremelanotide (PT-141) pass as components of approved drugs, and glutathione is compounded under FDA's interim policy. BPC-157, TB-500, CJC-1295 and most wellness peptides pass none of the tests, and biological products such as tesamorelin and hCG are excluded altogether.

+−Do 503A pharmacies have to follow cGMP?

No. Drugs compounded in line with section 503A are exempt from federal current good manufacturing practice requirements. They must use ingredients that meet USP or National Formulary standards and follow the USP chapter on pharmacy compounding, under the oversight of the state board of pharmacy. If a 503A pharmacy compounds outside the section, for example by making copies of an approved drug routinely, it loses the exemption and FDA treats the products as subject to cGMP.

+−Can a doctor's office buy compounded drugs for office use?

Only from a 503B outsourcing facility. FDA's guidance on the 503A prescription requirement says a 503A pharmacy needs a prescription for an identified patient, so prescriptions without patient names do not qualify; clinics, hospitals and practitioners can obtain non-patient-specific compounded drugs from registered outsourcing facilities, whose labels must then say 'Office Use Only'.

+−Are compounded drugs from a 503B facility FDA-approved?

No. Section 503B exempts qualifying compounded drugs from the FDA approval requirement, so FDA does not review their safety or effectiveness before they are sold. What it adds is FDA registration, cGMP and FDA inspection of the facility. FDA's 2026 warning letters to telehealth companies targeted marketing that implied compounded products were the same as approved drugs.

+−Can tesamorelin, hCG or growth hormone be compounded under 503A or 503B?

No. Biological products, which include any protein longer than 40 amino acids, are not eligible for the exemptions in either section, and since March 23, 2020 that includes former drug approvals deemed to be biologics licenses. FDA states plainly that biologics cannot be compounded. Tesamorelin is available lawfully only as brand Egrifta.

Sources

1. Regulatory21 U.S.C. 353a (FD&C Act section 503A): pharmacy compounding. Legal Information Institute, Cornell Law School; read October 10, 2026.
2. Regulatory21 U.S.C. 353b (FD&C Act section 503B): outsourcing facilities. Legal Information Institute, Cornell Law School; read October 10, 2026.
3. RegulatoryFDA. Compounding and the FDA: questions and answers (who inspects compounders, which quality standards apply, whether biologics can be compounded). Content current as of September 16, 2025; read October 10, 2026. (2025)
4. RegulatoryFDA. Information for outsourcing facilities (Drug Quality and Security Act of November 27, 2013; CGMP; risk-based inspections; adverse event and product reporting). Content current as of March 29, 2022; read October 10, 2026. (2022)
5. RegulatoryFDA. Registered outsourcing facilities: facilities registered under section 503B, with last inspection, Form 483 and action taken. Updated as of September 30, 2026; read October 10, 2026. (2026)
6. RegulatoryFDA. Bulk drug substances used in compounding under section 503B of the FD&C Act (conditions, interim categories), with the 503B bulks list updated August 21, 2023. Content current as of January 7, 2025; read October 10, 2026. (2025)
7. GuidelineFDA. Prescription requirement under section 503A of the Federal Food, Drug, and Cosmetic Act: guidance for industry (office stock, anticipatory compounding). December 2016. (2016)
8. GuidelineFDA. Compounded drug products that are essentially copies of a commercially available drug product under section 503A: guidance for industry. January 2018. (2018)
9. GuidelineFDA. Compounded drug products that are essentially copies of approved drug products under section 503B: guidance for industry. January 2018. (2018)
10. RegulatoryFederal Register. List of bulk drug substances for which there is a clinical need under section 503B: FDA proposes not to include semaglutide, tirzepatide and liraglutide (91 FR 23431, docket FDA-2018-N-3240). May 1, 2026. (2026)
11. RegulatoryFDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse event reports through May 31, 2026; adverse event reporting by pharmacies; salt forms; retatrutide). Content current as of October 1, 2026; read October 10, 2026. (2026)
12. RegulatoryFDA. Notice to compounders: changes that affect compounding as of March 23, 2020 (biological products with deemed biologics licenses are not eligible for the exemptions in sections 503A and 503B). Content current as of March 5, 2020; read October 10, 2026. (2020)
13. RegulatoryFDA. Warning letter to ProRx LLC, a registered outsourcing facility: tirzepatide compounded from bulk drug substance; October 15, 2025 recall of tirzepatide and semaglutide lots for lack of sterility assurance. MARCS-CMS 723704, April 7, 2026; read October 10, 2026. (2026)
14. RegulatoryFDA. Warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (503A): tirzepatide-niacinamide and semaglutide-cyanocobalamin products found to be essentially copies; templated significant-difference statements; insanitary conditions. MARCS-CMS 738238, September 18, 2026; read October 10, 2026. (2026)
15. StudySmith RM, Schaefer MK, Kainer MA, et al. Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med 2013;369:1598-609. (2013)